Paclitaxel

For research use only.

Catalog No.S1150 Synonyms: NSC 125973, PTX, Taxol, Onxal

162 publications

Paclitaxel Chemical Structure

CAS No. 33069-62-4

Paclitaxel (NSC 125973, PTX, Taxol, Onxal) is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.

Size Price Stock Quantity  
10mM (1mL in DMSO) EUR 89 In stock
EUR 68 In stock
EUR 265 In stock
EUR 461 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Paclitaxel has been cited by 162 publications

Purity & Quality Control

Choose Selective Antineoplastic and Immunosuppressive Antibiotics Inhibitors

Biological Activity

Description Paclitaxel (NSC 125973, PTX, Taxol, Onxal) is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.
Targets
Microtubule (human endothelial cells) [1]
0.1 pM
In vitro

Paclitaxel inhibits non-endothelial type human cells at 104 - to 105 -fold higher concentrations, with IC50 of 1 nM-10 nM. The selectivity of Paclitaxel inhibition of cell proliferation is also species specific, as mouse ECs are not sensitive to Paclitaxel at ultra low concentrations. Inhibition of human ECs by Paclitaxel at ultra low concentrations does not affect the cellular microtubule structure, and the treated cells do not show G2/M cell cycle arrest and apoptosis, suggesting a novel but as yet unidentified mechanism of action. In an in vitro angiogenesis assay, Paclitaxel at ultra low concentrations blocks human ECs from forming sprouts and tubes in the three-dimensional fibrin matrix. [1] In the presence of SMF, the efficient concentration of Paclitaxel on K562 cells is decreased from 50 to 10 ng/mL. The cell cycle arrest effect of Paclitaxel with or without SMF on K562 cells is correlated with DNA damage. [2] Paclitaxel alone causes a time-dependent inhibition of CDK1 in four cell lines including A549 cells, H358, H1395 cells and H1666 cells. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
TE-15 NV3FSmo4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3HdFBKSzVyPUCuNFAxOjh5IN88US=> NUjid2Z6W0GQR1XS
LC-2-ad MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\jToZKSzVyPUCuNFAxOzF5IN88US=> MmDnV2FPT0WU
RL95-2 NXfoV4FxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1P4cWlEPTB;MD6wNFA3PjhizszN MWDTRW5ITVJ?
MZ1-PC NIHxXIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLr[2FYUUN3ME2wMlAxODd{OTFOwG0> M{LlS3NCVkeHUh?=
TE-8 MkfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnL6TWM2OD1yLkCwNVE4KM7:TR?= MVnTRW5ITVJ?
SW954 NXqx[3B[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmm5TWM2OD1yLkCwNVE6KM7:TR?= NY\uN5B1W0GQR1XS
TE-11 NHTRc3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV:yNmNCUUN3ME2wMlAxOTJ|IN88US=> M{Pl[3NCVkeHUh?=
PSN1 M2rOOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\QSog4UUN3ME2wMlAxOTNizszN M{TpXnNCVkeHUh?=
MOLT-4 Mo\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTBwMECxOFkh|ryP MUPTRW5ITVJ?
697 NGexOHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXSOIxKSzVyPUCuNFAyPSEQvF2= MV3TRW5ITVJ?
ETK-1 M{S0R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXCTWM2OD1yLkCwNVUzKM7:TR?= NHzITW1USU6JRWK=
TE-10 MmrZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTBwMECxOVQh|ryP M33iSHNCVkeHUh?=
HUTU-80 NYLlOHZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTBwMECxOlgh|ryP M37a[3NCVkeHUh?=
NTERA-S-cl-D1 NFu4[4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTBwMECyNFkh|ryP NEjpeGxUSU6JRWK=
MFH-ino NUXLXoM4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml33TWM2OD1yLkCwNlY5KM7:TR?= MlTYV2FPT0WU
IA-LM NGGwTY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M164emlEPTB;MD6wNFI5KM7:TR?= MkTyV2FPT0WU
MC116 NFiw[m9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHe4blVKSzVyPUCuNFAzQDlizszN NHPQOGNUSU6JRWK=
RKO M3\VW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTBwMECyPVgh|ryP Mn3tV2FPT0WU
MRK-nu-1 M3vROWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTvTWM2OD1yLkCwNlk6KM7:TR?= MlL2V2FPT0WU
VA-ES-BJ MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTBwMECzJO69VQ>? MYDTRW5ITVJ?
KALS-1 NXuw[4VMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfrfJpKSzVyPUCuNFA{ODhizszN NEToUpZUSU6JRWK=
BB30-HNC M1H6bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrLR2dKUUN3ME2wMlAxOzF2IN88US=> NXS5SYRVW0GQR1XS
ACN MonVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPjS2NKSzVyPUCuNFA{OTZizszN M4PzeHNCVkeHUh?=
TE-9 NVHCWJFXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjXTWM2OD1yLkCwN|I3KM7:TR?= M4LCcnNCVkeHUh?=
SIG-M5 NYjYR2c{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXnT4RKSzVyPUCuNFA{OjdizszN MYnTRW5ITVJ?
no-10 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXOeXdKSzVyPUCuNFA{PjJizszN M2XrR3NCVkeHUh?=
EW-1 MoXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTBwMECzO|Eh|ryP Mm\rV2FPT0WU
SK-LMS-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULhbmVwUUN3ME2wMlAxPDBzIN88US=> M{LNRnNCVkeHUh?=
GT3TKB MkjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknwTWM2OD1yLkCwOFM1KM7:TR?= NXjieoRzW0GQR1XS
ES4 NVjVPYpkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofuTWM2OD1yLkCwOFQ6KM7:TR?= M2TXfHNCVkeHUh?=
IMR-5 NXPHSYR4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jvUGlEPTB;MD6wNFQ2KM7:TR?= NGj5SI9USU6JRWK=
NCI-H1648 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjxR3QxUUN3ME2wMlAxPDZ7IN88US=> M2fxdnNCVkeHUh?=
MV-4-11 NXX3UXJZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTBwMEC0O|Uh|ryP MknoV2FPT0WU
SK-UT-1 M3XhWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{K2VmlEPTB;MD6wNFQ5KM7:TR?= NWHaV5NUW0GQR1XS
NB13 NYjodIUzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfLT2FlUUN3ME2wMlAxPDlzIN88US=> MWjTRW5ITVJ?
DJM-1 MnfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHibYpKSzVyPUCuNFA2OyEQvF2= NF61c5VUSU6JRWK=
ES8 NYPWPIN2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzpd3BSUUN3ME2wMlAxPTN6IN88US=> NWXLemhzW0GQR1XS
TE-6 MkH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTBwMEC1O{DPxE1? MVjTRW5ITVJ?
KS-1 MlXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3j6eGlEPTB;MD6wNFU5OiEQvF2= MWrTRW5ITVJ?
TE-1 NHjpbZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4KwdWlEPTB;MD6wNFYxPiEQvF2= M3u2bnNCVkeHUh?=
ATN-1 M4P5dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1ezUWlEPTB;MD6wNFYxQSEQvF2= NF7SfIVUSU6JRWK=
A4-Fuk M{TlTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXBTWM2OD1yLkCwOlEyKM7:TR?= NYLPTGRtW0GQR1XS
ALL-PO MkTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUC1NZYxUUN3ME2wMlAxPjNizszN M1XZVXNCVkeHUh?=
BE-13 NInETY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3S5XWlEPTB;MD6wNFY{PiEQvF2= MU\TRW5ITVJ?
KM12 MljSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHteXRKSzVyPUCuNFA3OzdizszN MVLTRW5ITVJ?
NOS-1 NX6yRVVqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTBwMEC2OUDPxE1? NYnaNpRpW0GQR1XS
SW962 Mn;BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLlNY5KSzVyPUCuNFA3PjJizszN MnXHV2FPT0WU
OCUB-M M33rRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{K2UWlEPTB;MD6wNFY3OiEQvF2= M1zFfnNCVkeHUh?=
NCI-H510A NWSxU45QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XZTmlEPTB;MD6wNFY3PSEQvF2= NE[4SpFUSU6JRWK=
EW-16 MoX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLJTWM2OD1yLkCwOlk1KM7:TR?= NFfQW2dUSU6JRWK=
KGN MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTkPYFKSzVyPUCuNFA4OTJizszN M1f4RnNCVkeHUh?=
LS-411N M1OwZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnX6TWM2OD1yLkCwO|E4KM7:TR?= NGLZZ5NUSU6JRWK=
Becker M135SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYX3flhQUUN3ME2wMlAxPzJizszN NITYZ2hUSU6JRWK=
HC-1 Ml70S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVi2epp7UUN3ME2wMlAxPzJzIN88US=> M1f6eHNCVkeHUh?=
CESS MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTBwMEC3N|ch|ryP NWD2VYVxW0GQR1XS
KURAMOCHI MnPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHsU5hJUUN3ME2wMlAxPzR6IN88US=> MknuV2FPT0WU
TGBC24TKB Mn3qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDsNZhWUUN3ME2wMlAxPzV{IN88US=> Mmn3V2FPT0WU
SW982 M3:0dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTBwMEC3OlYh|ryP MVfTRW5ITVJ?
HCE-4 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITxUZVKSzVyPUCuNFA4PjdizszN NYDET2hGW0GQR1XS
LOUCY M1r4VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13mOmlEPTB;MD6wNFc4PSEQvF2= MX\TRW5ITVJ?
8-MG-BA NV36TYNDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTBwMEC3PVYh|ryP NWTvPHBzW0GQR1XS
HT-144 NX\vSGlOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHpT41lUUN3ME2wMlAxQCEQvF2= NX\tNmdbW0GQR1XS
LXF-289 MnXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTBwMEC4NVgh|ryP MYXTRW5ITVJ?
RS4-11 MoHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIX4bIFKSzVyPUCuNFA5OzZizszN M3;iTnNCVkeHUh?=
DEL NXrxfXN[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{D3RWlEPTB;MD6wNFg1PSEQvF2= MX3TRW5ITVJ?
OCI-AML2 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTBwMEC4OVIh|ryP Mm\zV2FPT0WU
CCRF-CEM M4XZWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInIeWZKSzVyPUCuNFA5PzFizszN MWrTRW5ITVJ?
A388 M1;adGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTBwMEC4O|Qh|ryP NFX4UmtUSU6JRWK=
KNS-42 MkPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLzV2pKSzVyPUCuNFA5QTFizszN NVXZRollW0GQR1XS
OVCAR-4 M171Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3STWM2OD1yLkCwPVA1KM7:TR?= MVLTRW5ITVJ?
NCI-H1355 NHP4OmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknKTWM2OD1yLkCwPVE1KM7:TR?= M{foPXNCVkeHUh?=
BL-70 MmrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zZPWlEPTB;MD6wNFk{KM7:TR?= MkLvV2FPT0WU
BL-41 M{\wdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLRTWM2OD1yLkCwPVM1KM7:TR?= MojvV2FPT0WU
A101D NV7BNFdoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTBwMEC5OkDPxE1? NYTFUlhSW0GQR1XS
HL-60 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\5RnJKSzVyPUCuNFA6PjZizszN NGCwcm1USU6JRWK=
COR-L279 M3LFNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnFfYM2UUN3ME2wMlAxQTl7IN88US=> NUn6RnJ[W0GQR1XS
NCI-SNU-16 NGXvUXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTBwMEGwNFgh|ryP NUPCWG9HW0GQR1XS
Calu-6 NHHMSWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTBwMEGwNVIh|ryP MorCV2FPT0WU
SR MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHQR2RnUUN3ME2wMlAyODJ4IN88US=> MXHTRW5ITVJ?
QIMR-WIL NYW4bnJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTBwMEGwN|Mh|ryP MnG4V2FPT0WU
LB647-SCLC M1f1[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jNWmlEPTB;MD6wNVA2OSEQvF2= MkXUV2FPT0WU
RPMI-8226 NFHWbG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTBwMEGxNFIh|ryP NWHnbWc1W0GQR1XS
SK-PN-DW M4HGcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTBwMEGxNVIh|ryP NX;tUJQxW0GQR1XS
SF268 NHHldXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTqTWM2OD1yLkCxNVUyKM7:TR?= M2fleXNCVkeHUh?=
HD-MY-Z MlnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;VTWlEPTB;MD6wNVE3OyEQvF2= MlTaV2FPT0WU
DOHH-2 Mn3KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PTfWlEPTB;MD6wNVIxOyEQvF2= M2nxXXNCVkeHUh?=
SCC-3 M{LTemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPuclREUUN3ME2wMlAyOjB2IN88US=> NXPmfVVMW0GQR1XS
ST486 M{XDdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn[0TWM2OD1yLkCxNlA1KM7:TR?= NYrOcYVLW0GQR1XS
NALM-6 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGm1WVFKSzVyPUCuNFEzOTRizszN NW[4ZVlJW0GQR1XS
NCI-H1436 MlLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYT1VGptUUN3ME2wMlAyOjNzIN88US=> M4rHenNCVkeHUh?=
KE-37 Mm\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTBwMEGyN|Qh|ryP NULlUJRtW0GQR1XS
RPMI-8402 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLtd4JJUUN3ME2wMlAyOjV4IN88US=> NIr0RVdUSU6JRWK=
RXF393 NEXvdZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHLTWM2OD1yLkCxNlU4KM7:TR?= MUHTRW5ITVJ?
KARPAS-45 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonHTWM2OD1yLkCxNlch|ryP MmrBV2FPT0WU
HOP-62 M1X5NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTBwMEGyO|Yh|ryP M{TUNHNCVkeHUh?=
ES1 Mo\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fPWmlEPTB;MD6wNVI5QCEQvF2= MYrTRW5ITVJ?
L-363 NXLMWnZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHGUZgxUUN3ME2wMlAyOzVzIN88US=> M3zjVXNCVkeHUh?=
GI-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTxem5QUUN3ME2wMlAyOzd|IN88US=> MYLTRW5ITVJ?
CTV-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETIWVlKSzVyPUCuNFE1PzhizszN NX;WbZU3W0GQR1XS
TE-5 MkO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXntUnpVUUN3ME2wMlAyPDl4IN88US=> NEG1UW1USU6JRWK=
SNU-C2B NFf4RZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkT2TWM2OD1yLkCxOFk3KM7:TR?= MlnzV2FPT0WU
K-562 NELrS4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DvR2lEPTB;MD6wNVUyPiEQvF2= MnrMV2FPT0WU
SNB75 NEnrfo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3seIhKSzVyPUCuNFE2PCEQvF2= NVrxUHlKW0GQR1XS
MOLT-13 NGrKcYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTBwMEG2N|ch|ryP NVy5XXZKW0GQR1XS
LS-123 NV3IPW1{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NImy[JVKSzVyPUCuNFE3PjRizszN MmTqV2FPT0WU
NCI-SNU-5 NYDmb3NZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4C1S2lEPTB;MD6wNVcxOSEQvF2= MmHtV2FPT0WU
Daudi MmPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nn[mlEPTB;MD6wNVcxQCEQvF2= NH;nZ3JUSU6JRWK=
A253 MmTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jKOGlEPTB;MD6wNVc{QCEQvF2= NYrGcXVIW0GQR1XS
TGBC1TKB MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGX5XZNKSzVyPUCuNFE4PTJizszN Mmj3V2FPT0WU
SJSA-1 NWXN[nBFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYX0d2t1UUN3ME2wMlAyPzZ5IN88US=> MUjTRW5ITVJ?
NCCIT MkjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\wN2lEPTB;MD6wNVc3QSEQvF2= MlryV2FPT0WU
NCI-H69 M2XOVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnreGZOUUN3ME2wMlAyPzd6IN88US=> MVLTRW5ITVJ?
SH-4 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmW5TWM2OD1yLkCxPFk2KM7:TR?= MUjTRW5ITVJ?
HCC1187 MoT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjkUlh2UUN3ME2wMlAyQTJ2IN88US=> NGK2OY9USU6JRWK=
HCC1599 NY\IcJJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrzTWM2OD1yLkCyNFIh|ryP NVr2T4doW0GQR1XS
ONS-76 Mm\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTBwMEKwN|Yh|ryP M{X2UXNCVkeHUh?=
KU812 M13YTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zmbGlEPTB;MD6wNlA{QSEQvF2= MXvTRW5ITVJ?
ML-2 MlzvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTBwMEKwOFch|ryP NWnwWVI2W0GQR1XS
HCE-T NGm5Z3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;uTZBKUUN3ME2wMlAzODl{IN88US=> NWLQNnNGW0GQR1XS
NCI-H446 M1u5eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\pSFZKSzVyPUCuNFIyOTJizszN NEDHcpFUSU6JRWK=
RPMI-6666 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLPTWM2OD1yLkCyNVQ6KM7:TR?= NHPTNpJUSU6JRWK=
MOLT-16 NFS4WYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;DOZRLUUN3ME2wMlAzOTV|IN88US=> MUPTRW5ITVJ?
JiyoyeP-2003 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTzTWM2OD1yLkCyNVc3KM7:TR?= NGnRPWlUSU6JRWK=
MHH-PREB-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIW4ZYNKSzVyPUCuNFIyQTFizszN M1P0SHNCVkeHUh?=
MC-CAR NX[zUpRDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrjbGI{UUN3ME2wMlAzOzJ4IN88US=> MWjTRW5ITVJ?
BC-3 M3zibGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrDVFdOUUN3ME2wMlAzOzR2IN88US=> M{nReXNCVkeHUh?=
KINGS-1 Ml7JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIS5N21KSzVyPUCuNFI{PTVizszN NHjCZ4VUSU6JRWK=
PF-382 MoHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPLTWM2OD1yLkCyN|c5KM7:TR?= Mln0V2FPT0WU
J-RT3-T3-5 M2TKZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfETWM2OD1yLkCyN|g{KM7:TR?= MmX3V2FPT0WU
SF539 NY\BUWlNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TkcmlEPTB;MD6wNlQxOSEQvF2= MWPTRW5ITVJ?
LB831-BLC M{PM[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjaVlNNUUN3ME2wMlAzPDh3IN88US=> MXzTRW5ITVJ?
DMS-114 M{fuOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILtd4pKSzVyPUCuNFI2ODJizszN MV;TRW5ITVJ?
LB1047-RCC NHXzfnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHQV5VEUUN3ME2wMlAzPTFizszN NVvNR3NZW0GQR1XS
LB771-HNC NX\lWGlkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTBwMEK1N|Qh|ryP NVXmXJZTW0GQR1XS
BB65-RCC NEnyeZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTBwMEK1N|Qh|ryP M3PPXXNCVkeHUh?=
BV-173 NH3XPGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvHTWM2OD1yLkCyOVU1KM7:TR?= M3TXVXNCVkeHUh?=
ARH-77 M1K0fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn21TWM2OD1yLkCyOlAyKM7:TR?= NHvMUm5USU6JRWK=
IST-MEL1 NVfsd|hjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;2V|dzUUN3ME2wMlAzPjJ|IN88US=> NX\1O5pFW0GQR1XS
NB1 MmPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfMW4hUUUN3ME2wMlAzPjh5IN88US=> NXjC[W5GW0GQR1XS
EoL-1-cell M{HOTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PRVmlEPTB;MD6wNlY5QCEQvF2= NF76d5pUSU6JRWK=
KY821 M{T6bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH:wVJdKSzVyPUCuNFI3QTdizszN NWG5XGtMW0GQR1XS
CMK NUj1NHlZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzpfpdKSzVyPUCuNFI4OzRizszN NHvZUpJUSU6JRWK=
NCI-H2126 NE\3SmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTBwMEK3Olgh|ryP MmrDV2FPT0WU
NCI-H526 MkHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDiUINKSzVyPUCuNFI5QTFizszN M1T5THNCVkeHUh?=
COLO-684 M2C4U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTBwMEK5NFgh|ryP NF7UTm1USU6JRWK=
NCI-H747 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{P5emlEPTB;MD6wNlk{OyEQvF2= NEDEbFBUSU6JRWK=
JAR NGrrSZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7xNmV{UUN3ME2wMlAzQTR4IN88US=> NEHxOWhUSU6JRWK=
MEG-01 Ml\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXux[JVPUUN3ME2wMlAzQTd6IN88US=> M{TIbnNCVkeHUh?=
MONO-MAC-6 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7wc5pyUUN3ME2wMlA{ODJ|IN88US=> MVTTRW5ITVJ?
IST-SL1 M2jmUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTBwMEOwOFIh|ryP M1jSSnNCVkeHUh?=
CPC-N MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmC2TWM2OD1yLkCzNFc6KM7:TR?= NEXvSnJUSU6JRWK=
NCI-H1963 MoHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTBwMEOxN|Eh|ryP MYrTRW5ITVJ?
K052 NVTaUIJTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTBwMEOyOFch|ryP MVzTRW5ITVJ?
KM-H2 NIrNNpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFf4fYhKSzVyPUCuNFM{ODdizszN M4jGU3NCVkeHUh?=
TE-12 NYHjOoo4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPLTWM2OD1yLkCzN|A6KM7:TR?= MljoV2FPT0WU
TK10 M{TRO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfrTWM2OD1yLkCzN|U3KM7:TR?= NWfvbFNoW0GQR1XS
NMC-G1 NU\4O3NFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLxTIRzUUN3ME2wMlA{PDV{IN88US=> NHv2bG1USU6JRWK=
no-11 M4nKOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWX5dZhrUUN3ME2wMlA{PDd6IN88US=> MWTTRW5ITVJ?
NCI-H524 MoLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHWdphKSzVyPUCuNFM2OjlizszN M1\FUHNCVkeHUh?=
MHH-CALL-2 NX7ib2ZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTBwMEO1OlIh|ryP NIXvR5ZUSU6JRWK=
GB-1 M2DLV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPhZmdKSzVyPUCuNFM3KM7:TR?= NFe3T25USU6JRWK=
OPM-2 NUPwTHBTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2[zXWlEPTB;MD6wN|Y4OyEQvF2= MmnPV2FPT0WU
RH-1 M4G3SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jTOGlEPTB;MD6wN|gyQSEQvF2= MkjUV2FPT0WU
NCI-H64 NX;NbVZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfZTFBKSzVyPUCuNFM5PTdizszN MVnTRW5ITVJ?
EVSA-T NYGxRoV3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTBwMEO5NlMh|ryP MWTTRW5ITVJ?
KARPAS-299 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfNUZNGUUN3ME2wMlA{QThizszN M37ae3NCVkeHUh?=
MZ7-mel NInLV2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTyTWM2OD1yLkC0NFQh|ryP Mn30V2FPT0WU
LB373-MEL-D Mm\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFi2dmlKSzVyPUCuNFQyODVizszN MX;TRW5ITVJ?
HEL NIDwPFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjtTZVKSzVyPUCuNFQyPCEQvF2= M2X1b3NCVkeHUh?=
SW872 NFjGUW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nVRWlEPTB;MD6wOFIyKM7:TR?= Ml\XV2FPT0WU
DU-4475 NGDZT2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;PTWM2OD1yLkC0NlQ1KM7:TR?= NFnUUnRUSU6JRWK=
IST-SL2 NGLaVoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTwS5gzUUN3ME2wMlA1Ojd3IN88US=> NGLFPVRUSU6JRWK=
NCI-H82 MlOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTBwMESzNFch|ryP MWrTRW5ITVJ?
LC4-1 M3;yZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfXTlZKSzVyPUCuNFQ{PTFizszN M3\adXNCVkeHUh?=
HDLM-2 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\FflRKSzVyPUCuNFQ{QTJizszN M{C2Z3NCVkeHUh?=
MMAC-SF MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;FeWlEPTB;MD6wOFU{PCEQvF2= M1:2bHNCVkeHUh?=
L-540 NUnrO3h7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX72e|BtUUN3ME2wMlA1PjN7IN88US=> MoTEV2FPT0WU
MZ2-MEL NWr2UGEzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3se4lxUUN3ME2wMlA1PzR{IN88US=> MUfTRW5ITVJ?
LU-134-A MoPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTBwMES3O|Mh|ryP MlX5V2FPT0WU
UACC-257 NYLCUohmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnv2TWM2OD1yLkC0PFQ6KM7:TR?= MoLTV2FPT0WU
NCI-H1581 NF\lSIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HlTGlEPTB;MD6wOFk2OyEQvF2= NW\idZMzW0GQR1XS
NB17 Mlj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnz4TWM2OD1yLkC0PVc6KM7:TR?= M2LEVXNCVkeHUh?=
SBC-1 NIXIbGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDNTWM2OD1yLkC1NFQzKM7:TR?= NUjSd4tbW0GQR1XS
TALL-1 NGHaXlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moj3TWM2OD1yLkC1NFQ2KM7:TR?= Mme4V2FPT0WU
NCI-H1304 NF:4T5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTBwMEWyNFgh|ryP NWLKbm5QW0GQR1XS
NEC8 NG[xXJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4ra[2lEPTB;MD6wOVI5PiEQvF2= Ml32V2FPT0WU
CAL-148 MkD1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTBwMEW0N|kh|ryP MWLTRW5ITVJ?
CGTH-W-1 MmLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vySmlEPTB;MD6wOVQ1QSEQvF2= M1TZS3NCVkeHUh?=
NCI-H889 M3THUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TZb2lEPTB;MD6wOVU6OiEQvF2= M3HCVXNCVkeHUh?=
GR-ST Mon2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTBwMEW2NlEh|ryP MVLTRW5ITVJ?
KARPAS-422 M{PjPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PTUWlEPTB;MD6wOVY2KM7:TR?= NWTDTldHW0GQR1XS
RPMI-8866 Mm\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTBwMEW3NVIh|ryP NF2wWJJUSU6JRWK=
SCLC-21H NID1ZnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzQXZdKSzVyPUCuNFU5QDRizszN M4nWbnNCVkeHUh?=
COR-L88 NX:0UnM1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTBwMEW5Nlch|ryP NUP0do1SW0GQR1XS
LU-139 NYqwVXB[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDPTWM2OD1yLkC1PVg3KM7:TR?= MkX3V2FPT0WU
SF126 NEPoXFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LtT2lEPTB;MD6wOlE{OyEQvF2= NWm3emFTW0GQR1XS
NCI-H1882 NIT1UGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XrUmlEPTB;MD6wOlQzPCEQvF2= MkjSV2FPT0WU
EW-24 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTBwME[0PFMh|ryP NI[wZ2hUSU6JRWK=
CP67-MEL NEThN|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33lZWlEPTB;MD6wOlgyKM7:TR?= MnG4V2FPT0WU
DG-75 Mn;qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTBwME[4PVkh|ryP M3PpdXNCVkeHUh?=
LOXIMVI NV:3SGRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzrTWM2OD1yLkC3NFI5KM7:TR?= M4PiRnNCVkeHUh?=
HH Mnu1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnaSY1CUUN3ME2wMlA4OTV5IN88US=> MXHTRW5ITVJ?
K5 M3XBOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TRNGlEPTB;MD6wO|IzPiEQvF2= M3KzcXNCVkeHUh?=
EC-GI-10 MkW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2Xqe2lEPTB;MD6wO|I2PyEQvF2= Mk\sV2FPT0WU
SK-N-DZ MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTBwMEezNFch|ryP M{fH[HNCVkeHUh?=
A3-KAW NXLJVJJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTBwMEezOVEh|ryP NUHpTlN7W0GQR1XS
MLMA MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TORWlEPTB;MD6wO|Q3PSEQvF2= MmrOV2FPT0WU
LB996-RCC M4XtbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfaTWM2OD1yLkC3O|A4KM7:TR?= MlzTV2FPT0WU
OS-RC-2 NXGye49lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;lbGxKSzVyPUCuNFc4PDhizszN NGq1N|FUSU6JRWK=
CTB-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTBwMEe4NUDPxE1? NHrYWFFUSU6JRWK=
IST-MES1 MmXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mln0TWM2OD1yLkC3PVEzKM7:TR?= NWT1eWsyW0GQR1XS
LS-1034 NELHXIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTBwMEiwN|Uh|ryP MYXTRW5ITVJ?
HT NGfPW2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfwZ2RZUUN3ME2wMlA5ODh4IN88US=> NXrL[mtlW0GQR1XS
NCI-H2141 NIXhcItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWW2bpVYUUN3ME2wMlA5OSEQvF2= MXLTRW5ITVJ?
LB2518-MEL M3WzPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvXR49qUUN3ME2wMlA5OTRzIN88US=> M3K0bHNCVkeHUh?=
GI-ME-N NVXPc4VGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\QWHZCUUN3ME2wMlA5PDV{IN88US=> M2\FTXNCVkeHUh?=
TGW MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTBwMEi2NFch|ryP MnzSV2FPT0WU
SK-NEP-1 MofuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrHeZhKSzVyPUCuNFg3PDFizszN NYDtNJpKW0GQR1XS
NOMO-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTBwMEmyO|Uh|ryP NYDlVlFUW0GQR1XS
ES6 Mm\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPHdZVKSzVyPUCuNFk2QDlizszN MmLDV2FPT0WU
NCI-H209 NUfUTGp5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33VWmlEPTB;MD6wPVc5PiEQvF2= MWjTRW5ITVJ?
GAK NXrTcXdtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTSOlJIUUN3ME2wMlExOTZizszN MUXTRW5ITVJ?
BC-1 M{XOWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvvepJRUUN3ME2wMlExOzZzIN88US=> M1PoUHNCVkeHUh?=
KLE M4j5Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHFWHBLUUN3ME2wMlExPDR|IN88US=> NUXLRYptW0GQR1XS
EW-3 NUXyNIhNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\KOGlEPTB;MD6xNFk5KM7:TR?= MlfsV2FPT0WU
NKM-1 NVnqcJN{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzsR5hjUUN3ME2wMlEyOSEQvF2= M{Tqc3NCVkeHUh?=
D-336MG MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjNRVNKSzVyPUCuNVEzPDRizszN NIXxTVZUSU6JRWK=
NB69 NH\l[5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTBwMUGzNFEh|ryP MXPTRW5ITVJ?
D-263MG MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnwTWM2OD1yLkGxO|EzKM7:TR?= NF70W3hUSU6JRWK=
KP-N-YS MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInnRoFKSzVyPUCuNVIzQTFizszN MkLiV2FPT0WU
NCI-H1155 NIDiPFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3Kd5dwUUN3ME2wMlEzPTV6IN88US=> NVP2fZN2W0GQR1XS
BOKU NHniRmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPVNVVKSzVyPUCuNVI2PzlizszN MlHmV2FPT0WU
LAMA-84 M{DRcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\LTWM2OD1yLkGyPVkh|ryP M1ezNnNCVkeHUh?=
Raji MkPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTEO3RKSzVyPUCuNVMyOTdizszN MUjTRW5ITVJ?
LU-65 M4i4emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3T6XGlEPTB;MD6xN|MxPyEQvF2= MXfTRW5ITVJ?
NCI-H187 MluwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nZfmlEPTB;MD6xN|kzPCEQvF2= M33ue3NCVkeHUh?=
GCIY NEPOWXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonnTWM2OD1yLkG0PVAyKM7:TR?= MVHTRW5ITVJ?
NCI-H2107 M4HoVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTBwMUWwPEDPxE1? MYrTRW5ITVJ?
NCI-H1522 MlW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTBwMUWyOlYh|ryP NXraNo1ZW0GQR1XS
NB6 M1ThZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1viSWlEPTB;MD6xOVYzOyEQvF2= NGjoO|lUSU6JRWK=
EM-2 M2X4S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzIV|BoUUN3ME2wMlE2PzB4IN88US=> M3\LdHNCVkeHUh?=
HCC2218 NVK2S2hST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY[2SY0{UUN3ME2wMlE2QThizszN MWfTRW5ITVJ?
NCI-H748 MlfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3L5SmlEPTB;MD6xOlM4PiEQvF2= MX3TRW5ITVJ?
MS-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{K0R2lEPTB;MD6xOlU{PyEQvF2= NYfXZ4dGW0GQR1XS
NB5 NIX3dpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTwTWM2OD1yLkG2OVk4KM7:TR?= MUjTRW5ITVJ?
OMC-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fGW2lEPTB;MD6xOlY5QCEQvF2= M3e0ZnNCVkeHUh?=
NCI-H345 M13RSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmr5TWM2OD1yLkG2PVI5KM7:TR?= MYDTRW5ITVJ?
L-428 NVnDcWhZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHm5bHRKSzVyPUCuNVY6PDVizszN NHK4U|lUSU6JRWK=
SCH Ml\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnkW|RKSzVyPUCuNVg3QDVizszN NVLYc5ExW0GQR1XS
NCI-H1417 NInqdWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjCUFJkUUN3ME2wMlE6OjJ5IN88US=> NGW4b49USU6JRWK=
COLO-320-HSR NW\McFEzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGG4O2tKSzVyPUCuNVk2OzJizszN NYjDPXp6W0GQR1XS
BT-474 NFPwPVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLqbVBKSzVyPUCuNlA5QTJizszN MVrTRW5ITVJ?
GDM-1 NUG4NJJNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;aTWM2OD1yLkKxPVcyKM7:TR?= MVvTRW5ITVJ?
NCI-H2196 NWDUZW5YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTBwMkKyN|Uh|ryP NVHuOW1YW0GQR1XS
KP-N-RT-BM-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTBwMkKzOFkh|ryP MYjTRW5ITVJ?
KNS-81-FD NEH1XmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3uyN2lEPTB;MD6yNlk2QCEQvF2= MUHTRW5ITVJ?
COLO-668 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF34e4lKSzVyPUCuNlM3PzVizszN M2WxXnNCVkeHUh?=
C2BBe1 M1:xPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LRe2lEPTB;MD6yOlc1PyEQvF2= NWTEOFZ{W0GQR1XS
Ramos-2G6-4C10 M1rNNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;ifHVKSzVyPUCuNlY6PTRizszN MYrTRW5ITVJ?
CAS-1 NIC0Zm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmT2TWM2OD1yLkK3NFk3KM7:TR?= MlzvV2FPT0WU
GOTO NXzTSpZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3LTWM2OD1yLkK3PFk1KM7:TR?= NH;kZ2JUSU6JRWK=
LP-1 M4raeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzJRYlwUUN3ME2wMlI5ODV5IN88US=> M4\FT3NCVkeHUh?=
NCI-SNU-1 M13wS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTBwMkm0NlIh|ryP M1nK[nNCVkeHUh?=
EB-3 NITWVpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPMTWM2OD1yLkK5PVc6KM7:TR?= M4DNenNCVkeHUh?=
MHH-NB-11 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXe1Z4RSUUN3ME2wMlMxPDB{IN88US=> MX3TRW5ITVJ?
SK-N-FI MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTBwM{G2PVIh|ryP NH7Pd3VUSU6JRWK=
HCC2157 NXHCb3dXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVW0VWR5UUN3ME2wMlM{QTF|IN88US=> NE\3R4RUSU6JRWK=
SIMA NX7VZ|lrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3z3N2lEPTB;MD6zOFU5OSEQvF2= NE\hN2FUSU6JRWK=
MDA-MB-134-VI MkS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFz3PJVKSzVyPUCuN|Y6OjhizszN NUSyW2l{W0GQR1XS
NCI-H1694 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3TcY9KSzVyPUCuN|ch|ryP NEjjXVhUSU6JRWK=
EHEB Mn7CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTBwM{mwPFUh|ryP NYHUbpltW0GQR1XS
U-266 NHnXOo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXv2dJRjUUN3ME2wMlM6QDR4IN88US=> NYLYPZpTW0GQR1XS
LC-1F M{LEdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnX5TWM2OD1yLkSzO|Y2KM7:TR?= Mn7EV2FPT0WU
SHP-77 NH3WR29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3wU5dUUUN3ME2wMlQ4QDV3IN88US=> NGrNNHBUSU6JRWK=
LS-513 NHTCe4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7ETWM2OD1yLkS5N|A4KM7:TR?= MkHvV2FPT0WU

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-ERK / ERK; 

PubMed: 20068074     


Paclitaxel pulse induces phospho-ERK. Paclitaxel (6ug/mL) was pulsed over 10min to 4hr prior to cell harvesting. A biphasic activation is observed in the resistant cells.

MARCKS (pSer159/163); 

PubMed: 26015406     


Paclitaxel treatment induces activation of MARCKS and Src in TNBC cells. Cells were incubated with various doses of paclitaxel as indicated. After 24 hours, cells were collected and subjected to Western blot analysis.

Src (pTyr416); 

PubMed: 26015406     


Paclitaxel treatment induces activation of MARCKS and Src in TNBC cells. Cells were incubated with various doses of paclitaxel as indicated. After 24 hours, cells were collected and subjected to Western blot analysis.

p-JAK2 / p-STAT3 / p-AKT / p-MAPK / Bcl-xl / MCL-1; 

PubMed: 29849942     


OVCAR-8 and MDAH2774 cells were treated with ruxolitinib (20 μM), paclitaxel (10 nM) or the combination for 24 h. Whole cells were collected and determined for the change of STAT3, AKT and ERK pathways and expression of BCL-XL and MCL-1 by Western blot.

Id1; 

PubMed: 25344919     


(A) Paclitaxel suppressed Id1 expression in H520 cells in a time-dependent manner.

MARCKS; 

PubMed: 26015406     


Paclitaxel treatment induces activation of MARCKS and Src in TNBC cells. Cells were incubated with various doses of paclitaxel as indicated. After 24 hours, cells were collected and subjected to Western blot analysis.

20068074 26015406 29849942 25344919
Growth inhibition assay
Cell viability; 

PubMed: 28823711     


Paclitaxel reduces HeyA8 tumor cell viability in MTT assay.

28823711
Immunofluorescence
α-tubulin; 

PubMed: 22904633     


Cellular α-tubulin (red) was blotted by immunostaining and subsequent confocal microscopy 3 hours after A549 cells were treated with 12.5 nM of paclitaxel and 12.5 nM of PLGA-PEI-TAX, respectively. The same experiment was performed with 62.5 nM of paclitaxel and 62.5 nM of PLGA-PEI-TAX in A549/T12 cells. PLGA-PEI-TAX, poly(lactic-co-glycolic acid)-polyethylenimine nanoparticles loaded with paclitaxel.

Rab11a/BV9; 

PubMed: 29290815     


Paclitaxel reversed the DAVLBH-mediated inhibition of internalized VE-cadherin recycling back to the cell membrane. HUVECs pretreated with or without paclitaxel were treated with or without DAVLBH for 4 h. Quantification of BV9/Rab11a colocalization is shown (n = 3).

22904633 29290815
In vivo

The inhibition rations of Paclitaxel alone on BC-V and BC-ER tumors are 49.78% and 51.23%, respectively. Treatment of six cycles of 20 mg/kg Paclitaxel significantly reduces the percentages of Ki-67-positive cells to 20.4% in BC-V tumors and 25.1% in BC-ER tumors, respectively. [4]

Protocol

Cell Research:

[1]

- Collapse
  • Cell lines: Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs
  • Concentrations: 0.1-100 pM
  • Incubation Time: 72 hours
  • Method:

    Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs), human mammary epithelial cells (HMEpCs), human prostate epithelial cells (PrEpCs) and human umbilical artery smooth muscle cells (UASMCs) are cultured. Cell proliferations are performed in 96-well plates using cells between passages 6 and 12. Cells are seeded at 3000–5000 cells/well and allowed to attach for 4 hours. Paclitaxel, diluted in culture medium, is added in quadruplicate wells and the cells ae incubated for 3 days before MTS reagents are added to quantitate the live cells in each well.


    (Only for Reference)
Animal Research:

[4]

- Collapse
  • Animal Models: Female, 20-22 g homozygous nude athymic mice with BC-V and BC-ER tumors
  • Dosages: 20 mg/kg
  • Administration: Administered via i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 171 mg/mL (200.25 mM)
Water Insoluble
Ethanol ''18 mg/mL
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+40% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
6mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 853.91
Formula

C47H51NO14

CAS No. 33069-62-4
Storage powder
in solvent
Synonyms NSC 125973, PTX, Taxol, Onxal
Smiles CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04252768 Not yet recruiting Drug: Eftilagimod Alpha|Drug: Paclitaxel Metastatic Breast Cancer Immutep S.A. June 2021 Phase 1
NCT04526470 Not yet recruiting Drug: Alpelisib + Paclitaxel Solid Tumor|Stomach Cancer Seoul National University Bundang Hospital September 1 2020 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I am interested in the product S1150 for in vivo studies, could you please give some suggestions for the formulation?

  • Answer:

    S1150 in 1% DMSO+30% polyethylene glycol+1% Tween 80 at 30mg/ml is a suspension. If the you want to inject it, there is another vehicle, 5% DMSO+5% Tween 80+ddH2O. S1150 can dissolve in it at 2.5mg/ml as a clear solution. It is a common formulation we used, but is not cited from reference.

  • Question 2:

    the compound was dissolved into 1ml DMSO and diluted with 1x PBS or water (500ul + 9.5 ml PBS or water). I found the white precipitation goes out. How to figure it out?

  • Answer:

    Paclitaxel has very low solubility in water based solution and that's why it precipitated out once you dilute the stock with water. The vehicle we suggest is: 1% DMSO+30% polyethylene glycol+1% Tween 80.

Tags: buy Paclitaxel | Paclitaxel supplier | purchase Paclitaxel | Paclitaxel cost | Paclitaxel manufacturer | order Paclitaxel | Paclitaxel distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID